From signals to support: rethinking pharma media in the moments that matter

When a parent searches 'is my child's inhaler working?' at 2am, they are not looking for brand messaging. They are looking for reassurance, clarity and a next step. That moment – specific, emotional and unplanned – is where pharma media needs to be. Not as an ad, but as a credible, useful presence.

The shift from mass-reach to precision in pharma media is not new. What is new is the ability to act on individual signals in real time: to understand where someone is in their health journey and respond with the right support at the right moment.

From campaigns to connected signals

Most pharma media still operates in campaign cycles: plan, execute, measure, repeat. But patients don't experience their conditions in campaign windows. A newly diagnosed Type 2 diabetes patient doesn't wait for Q3 to start worrying about insulin options. A caregiver managing a parent's dementia doesn't pause during a media dark period.

The opportunity is to move from scheduled outreach to signal-led engagement, where the system continuously reads behavioural, contextual and clinical signals and adapts what it delivers.

This is not about automation. Automation follows pre-set rules. Adaptive media rewrites the rules based on what it learns from live data.

What 'moments that matter' actually means

'Moments that matter' is one of the most overused phrases in healthcare marketing. But when applied with real data, it becomes operational rather than aspirational.

Consider a patient recently prescribed a biologic for psoriasis. In the first week, their information needs centre on administration: how to inject, what to expect, how to store the medication. By week four, their concerns shift to efficacy: is it working? What do others experience? By month three, they may be weighing whether to stay on therapy or switch.

Each of these moments has a different emotional register, a different information need and a different optimal channel. A display ad optimised for reach will miss most of them. A connected system that reads the signals won't.

The infrastructure behind relevance

Delivering this kind of precision requires more than good creative or smart targeting. It requires an intelligence layer that connects data, media, CRM, field activity and measurement in real time.

At WPP, we've built this through decades of healthcare provider data, visibility across millions of healthcare professionals and data tied to hundreds of millions of households. We combine this with prescription claims, audience signals and secondary sources to understand where patients and physicians are in their journey and what support is most relevant.

This connected intelligence has delivered measurable results: a 57% uplift in media engagement over traditional campaigns and up to 5:1 incremental ROI across healthcare brands.

Rethinking measurement

If the model changes, measurement must change with it. Traditional pharma media metrics – impressions, clicks, cost-per-action – capture volume but not value. They tell you how many people saw something, not whether it mattered.

Signal-led media demands signal-led measurement: did the right message reach the right person at the right moment? Did it move them forward in their journey? Did it build or erode trust?

These are harder questions to answer. But they are the right ones.

Why this matters now

The healthcare landscape is becoming more complex, not less. Patients are more informed, more empowered and more sceptical. Physicians are time-poor and data-rich. AI tools are reshaping how both groups seek and process information.

In this environment, the brands that win will not be the loudest. They will be the most useful – present when needed, absent when not, always credible.

That 2am parent searching about their child's inhaler deserves better than a retargeted banner. They deserve a system that understands the moment and responds with genuine support.

That is the future of pharma media. Not more presence, but more relevance.